Analysts Set Genmab A/S (NASDAQ:GMAB) Price Target at $45.20

Genmab A/S (NASDAQ:GMAB - Get Free Report) has received an average recommendation of "Moderate Buy" from the ten ratings firms that are currently covering the stock, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, three have assigned a hold recommendation and six have issued a buy recommendation on the company. The average 1 year target price among brokerages that have covered the stock in the last year is $45.20.

A number of analysts have weighed in on the stock. Sanford C. Bernstein upgraded shares of Genmab A/S from a "strong sell" rating to a "hold" rating in a research note on Friday, December 20th. BMO Capital Markets reissued an "outperform" rating and set a $48.00 price target (up previously from $46.00) on shares of Genmab A/S in a research report on Friday, November 8th. Redburn Atlantic began coverage on Genmab A/S in a research report on Tuesday, October 8th. They issued a "buy" rating on the stock. Finally, HC Wainwright reissued a "buy" rating and issued a $50.00 target price on shares of Genmab A/S in a report on Wednesday, January 8th.

Institutional Trading of Genmab A/S

A number of hedge funds have recently bought and sold shares of the company. Two Sigma Advisers LP increased its position in shares of Genmab A/S by 84.1% during the 3rd quarter. Two Sigma Advisers LP now owns 615,100 shares of the company's stock valued at $14,996,000 after purchasing an additional 280,900 shares during the last quarter. Cubist Systematic Strategies LLC increased its holdings in Genmab A/S by 109.7% during the second quarter. Cubist Systematic Strategies LLC now owns 278,541 shares of the company's stock valued at $7,000,000 after buying an additional 145,689 shares during the last quarter. Renaissance Technologies LLC raised its position in Genmab A/S by 7.6% in the second quarter. Renaissance Technologies LLC now owns 1,462,459 shares of the company's stock worth $36,752,000 after acquiring an additional 103,859 shares during the period. Sanctuary Advisors LLC purchased a new position in shares of Genmab A/S during the 2nd quarter worth $1,354,000. Finally, Natixis Advisors LLC grew its position in shares of Genmab A/S by 29.8% during the 3rd quarter. Natixis Advisors LLC now owns 206,563 shares of the company's stock valued at $5,036,000 after acquiring an additional 47,437 shares during the period. Hedge funds and other institutional investors own 7.07% of the company's stock.

Genmab A/S Trading Down 0.4 %

Genmab A/S stock traded down $0.08 during trading hours on Tuesday, hitting $21.64. 868,019 shares of the stock traded hands, compared to its average volume of 881,045. Genmab A/S has a one year low of $19.85 and a one year high of $31.88. The company has a market cap of $14.32 billion, a PE ratio of 21.01, a PEG ratio of 0.63 and a beta of 0.97. The firm's 50-day moving average price is $21.29 and its two-hundred day moving average price is $24.17.

Genmab A/S (NASDAQ:GMAB - Get Free Report) last announced its earnings results on Wednesday, November 6th. The company reported $0.29 earnings per share for the quarter, missing analysts' consensus estimates of $0.32 by ($0.03). Genmab A/S had a net margin of 23.49% and a return on equity of 14.64%. The business had revenue of $816.10 million for the quarter, compared to the consensus estimate of $838.20 million. During the same period in the prior year, the business posted $0.47 EPS. On average, sell-side analysts expect that Genmab A/S will post 1.28 earnings per share for the current fiscal year.

About Genmab A/S

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.